Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Effect of a mandatory research requirement on categorical resident academic productivity in a university-based general surgery residency.

Papasavas P, Filippa D, Reilly P, Chandawarkar R, Kirton O.

J Surg Educ. 2013 Nov-Dec;70(6):715-9. doi: 10.1016/j.jsurg.2013.09.003.

PMID:
24209646
2.
3.

Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification.

Matasar MJ, Shi W, Silberstien J, Lin O, Busam KJ, Teruya-Feldstein J, Filippa DA, Zelenetz AD, Noy A.

Ann Oncol. 2012 Jan;23(1):159-66. doi: 10.1093/annonc/mdr029. Epub 2011 Mar 17.

PMID:
21415238
4.

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, Straus D, Noy A, Palomba ML, O'Connor OA, Horwitz S, Weaver SA, Meikle JL, Filippa DA, Caravelli JF, Hamlin PA, Zelenetz AD.

J Clin Oncol. 2010 Apr 10;28(11):1896-903. doi: 10.1200/JCO.2009.26.5942. Epub 2010 Mar 8.

5.

High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.

Moskowitz CH, Yahalom J, Zelenetz AD, Zhang Z, Filippa D, Teruya-Feldstein J, Kewalramani T, Moskowitz AJ, Rice RD, Maragulia J, Vanak J, Trippett T, Hamlin P, Horowitz S, Noy A, O'Connor OA, Portlock C, Straus D, Nimer SD.

Br J Haematol. 2010 Mar;148(6):890-7. doi: 10.1111/j.1365-2141.2009.08037.x. Epub 2010 Jan 18.

6.

ALK-positive diffuse large B-cell lymphoma with the t(2;17)(p23;q23).

Zhang D, Denley RC, Filippa DA, Teruya-Feldstein J.

Appl Immunohistochem Mol Morphol. 2009 Mar;17(2):172-7. doi: 10.1097/PAI.0b013e31818629a8.

PMID:
19521280
7.

Immunohistochemical evaluation of FLI-1 in acute lymphoblastic lymphoma (ALL): a potential diagnostic pitfall.

Lin O, Filippa DA, Teruya-Feldstein J.

Appl Immunohistochem Mol Morphol. 2009 Oct;17(5):409-12. doi: 10.1097/PAI.0b013e3181972b6d.

PMID:
19349856
8.

Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.

Hoppe BS, Moskowitz CH, Filippa DA, Moskowitz CS, Kewalramani T, Zelenetz AD, Yahalom J.

J Clin Oncol. 2008 Apr 10;26(11):1858-64. doi: 10.1200/JCO.2007.15.4773. Epub 2008 Mar 10. Erratum in: J Clin Oncol. 2008 Aug 20;26(24):4053. Zelenet, Andrew D [corrected to Zelenetz, Andrew D].

PMID:
18332466
9.

Bcl-6 predicts improved prognosis in primary central nervous system lymphoma.

Levy O, Deangelis LM, Filippa DA, Panageas KS, Abrey LE.

Cancer. 2008 Jan 1;112(1):151-6.

10.

Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.

Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL.

Br J Haematol. 2007 Oct;139(2):224-33.

PMID:
17897298
11.

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.

Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, Zimman R, Drake L, Riedel ER, Hedvat CV, Teruya-Feldstein J, Filippa DA, Fleisher M, Nimer SD, Comenzo RL.

Br J Haematol. 2006 Jan;132(2):155-61.

PMID:
16398649
12.

Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.

Comenzo RL, Hassoun H, Kewalramani T, Klimek V, Dhodapkar M, Reich L, Teruya-Feldstein J, Fleisher M, Filippa D, Nimer SD.

Leukemia. 2006 Feb;20(2):345-9.

PMID:
16319952
13.

Globular hepatic amyloid: a diagnostic peculiarity that bears clinical significance.

Agaram N, Shia J, Klimstra DS, Lau N, Lin O, Erlandson RA, Filippa DA, Godwin TA.

Hum Pathol. 2005 Jul;36(7):845-9. Review.

PMID:
16084957
14.

Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.

Gupta S, Zhou P, Hassoun H, Kewalramani T, Reich L, Costello S, Drake L, Klimek V, Dhodapkar M, Teruya-Feldstein J, Hedvat C, Kalakonda N, Fleisher M, Filippa D, Qin J, Nimer SD, Comenzo RL.

Bone Marrow Transplant. 2005 Mar;35(5):441-7.

PMID:
15640822
15.

Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma.

Xiao Q, Shen N, Hedvat CV, Moskowitz CH, Sussman LK, Filippa DA, Zelenetz AD, Houldsworth J, Chaganti RS, Teruya-Feldstein J.

Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):211-5.

PMID:
15551733
16.

CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients.

Teruya-Feldstein J, Chiao E, Filippa DA, Lin O, Comenzo R, Coleman M, Portlock C, Noy A.

Ann Oncol. 2004 Nov;15(11):1673-9.

PMID:
15520070
17.

The p73 locus is commonly deleted in non-Hodgkin's lymphomas.

Stoffel A, Filippa D, Rao PH.

Leuk Res. 2004 Dec;28(12):1341-5.

PMID:
15475076
18.

The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.

Portlock CS, Qin J, Schaindlin P, Roistacher N, Myers J, Filippa D, Louie D, Zelenetz AD, O'Brien JP, Moskowitz C, Norton L, Yahalom J, Straus DJ, Bertino JR.

Ann Oncol. 2004 Oct;15(10):1495-503.

PMID:
15367410
19.

Epstein-Barr virus positive large B-cell lymphoma arising in a patient previously treated with Cladribine for hairy cell leukemia.

Bhargava R, Barbashina V, Filippa DA, Teruya-Feldstein J.

Leuk Lymphoma. 2004 May;45(5):1043-8.

PMID:
15291365
20.

Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease.

Portlock CS, Donnelly GB, Qin J, Straus D, Yahalom J, Zelenetz A, Noy A, O'Connor O, Horwitz S, Moskowitz C, Filippa DA.

Br J Haematol. 2004 Jun;125(6):701-8.

PMID:
15180859
21.

Molecular analysis of gastric washings in the diagnosis and monitoring of gastric lymphomas.

Chen B, Colleoni GW, Salazar PA, Lal P, Gerdes H, Filippa DA.

Hum Pathol. 2004 May;35(5):582-6.

PMID:
15138933
22.

Unusual abdominal tumors, case 2. Localized amyloid associated with gastric adenocarcinoma.

Chang DZ, Zhang JX, Filippa DA, Portlock CS.

J Clin Oncol. 2004 Apr 15;22(8):1520-2. No abstract available.

PMID:
15084626
23.

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.

Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz CH.

Blood. 2004 May 15;103(10):3684-8. Epub 2004 Jan 22.

PMID:
14739217
24.

Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association.

Cohen AD, Zhou P, Xiao Q, Fleisher M, Kalakonda N, Akhurst T, Chitale DA, Moscowitz C, Dhodapkar MV, Teruya-Feldstein J, Filippa D, Comenzo RL.

Br J Haematol. 2004 Feb;124(3):309-14.

PMID:
14717777
25.
26.

Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.

Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, Kolb D, Geller MD, Hassoun H, Kewalramani T, Comenzo RL, Coplan K, Chen YT, Jungbluth AA.

Cancer Immun. 2003 Jul 23;3:9.

27.

CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.

Pan D, Qin J, Farber C, O'Brien J, Filippa D, Portlock CS.

Leuk Lymphoma. 2003 Jun;44(6):967-71.

PMID:
12854895
28.
29.

Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma.

Hedvat CV, Hegde A, Chaganti RS, Chen B, Qin J, Filippa DA, Nimer SD, Teruya-Feldstein J.

Hum Pathol. 2002 Oct;33(10):968-74.

PMID:
12395368
30.

Expression of SSX genes in the neoplastic cells of Hodgkin's lymphoma.

Colleoni GW, Capodieci P, Tickoo S, Cossman J, Filippa DA, Ladanyi M.

Hum Pathol. 2002 May;33(5):496-502.

PMID:
12094374
31.

Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue.

Heath JA, Broxson EH Jr, Dole MG, Filippa DA, George D, Lyden D, Dunkel IJ.

J Pediatr Hematol Oncol. 2002 Feb;24(2):160-3.

PMID:
11998794
32.

Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases.

Shia J, Teruya-Feldstein J, Pan D, Hegde A, Klimstra DS, Chaganti RS, Qin J, Portlock CS, Filippa DA.

Am J Surg Pathol. 2002 Feb;26(2):216-24.

PMID:
11812943
33.

Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: application of tissue microarrays.

Hedvat CV, Jaffe ES, Qin J, Filippa DA, Cordon-Cardo C, Tosato G, Nimer SD, Teruya-Feldstein J.

Mod Pathol. 2001 Dec;14(12):1270-6.

34.

Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma.

Goy A, Gilles F, Remache Y, Filippa D, Portlock CS, Jhanwar SC, Zelenetz AD.

Leuk Lymphoma. 2001 Jan;40(3-4):419-23.

PMID:
11426565
35.

Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.

Noy A, Verma R, Glenn M, Maslak P, Rahman ZU, Keenan JR, Weiss M, Filippa D, Zelenetz AD.

Blood. 2001 Apr 1;97(7):1929-36.

PMID:
11264154
36.

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, Louie D, Gonzales M, Walits J, Coady-Lyons N, Qin J, Frank R, Bertino JR, Goy A, Noy A, O'Brien JP, Straus D, Portlock CS, Yahalom J.

Blood. 2001 Feb 1;97(3):616-23.

PMID:
11157476
37.
38.
39.

Extensive bone marrow necrosis associated with multiple myeloma.

Zhu AX, Niesvizky R, Hedrick E, Fata F, Filippa DA, Michaeli J.

Leukemia. 1999 Dec;13(12):2118-20. No abstract available.

40.

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.

Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD.

J Clin Oncol. 1999 Dec;17(12):3776-85.

PMID:
10577849
41.

Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas.

Cigudosa JC, Parsa NZ, Louie DC, Filippa DA, Jhanwar SC, Johansson B, Mitelman F, Chaganti RS.

Genes Chromosomes Cancer. 1999 Jun;25(2):123-33.

PMID:
10337996
42.

The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature.

Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, Brennan MF.

Cancer. 1999 Feb 1;85(3):706-17. Review.

PMID:
10091744
43.

Extramedullary hematopoiesis mimicking metastatic lung carcinoma.

Hsu FI, Filippa DA, Castro-Malaspina H, Downey RJ.

Ann Thorac Surg. 1998 Oct;66(4):1411-3.

PMID:
9800847
44.

Immunohistochemical analysis of murine CD95/Fas/Apo-1 receptor and its ultrastructural distribution in the thymus.

Ramos P, Gangi MD, Baren A, Filippa D, Elkon KB.

APMIS. 1997 Aug;105(8):597-602.

PMID:
9298096
45.

A case-control study of endometrial cancer in relation to reproductive, somatometric, and life-style variables.

Kalandidi A, Tzonou A, Lipworth L, Gamatsi I, Filippa D, Trichopoulos D.

Oncology. 1996 Sep-Oct;53(5):354-9.

PMID:
8784467
46.
47.

Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years.

Lieberman PH, Jones CR, Steinman RM, Erlandson RA, Smith J, Gee T, Huvos A, Garin-Chesa P, Filippa DA, Urmacher C, Gangi MD, Sperber M.

Am J Surg Pathol. 1996 May;20(5):519-52.

PMID:
8619419
48.

CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease.

Filippa DA, Ladanyi M, Wollner N, Straus DJ, O'Brien JP, Portlock C, Gangi M, Sun M.

Blood. 1996 Apr 1;87(7):2905-17.

PMID:
8639911
49.

Cytology of extranodal Ki-1 anaplastic large cell lymphoma.

Zakowski MF, Feiner H, Finfer M, Thomas P, Wollner N, Filippa DA.

Diagn Cytopathol. 1996 Mar;14(2):155-61.

PMID:
8964173
50.

Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma.

Jakubowski AA, Bajorin DF, Templeton MA, Chapman PB, Cody BV, Thaler H, Tao Y, Filippa DA, Williams L, Sherman ML, Garnick MB, Houghton AN.

Clin Cancer Res. 1996 Feb;2(2):295-302.

Supplemental Content

Loading ...
Support Center